Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
January 30, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies...
Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy
October 17, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy
October 16, 2018 07:05 ET
|
Axsome Therapeutics, Inc.
Conference call and webcast to be held today at 8:00 AM Eastern Time NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company...
Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy
October 16, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Narcolepsy is a debilitating, orphan neurological condition with limited treatment options Phase 2 trial set to start in 4Q 2018 with results anticipated in 1H 2019 Conference call and webcast...
Global Sleep Aids Market Will Reach US$80.8 Bn by 2020: Persistence Market Research
July 31, 2015 07:44 ET
|
Persistence Market Research
New York, July 31, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market Research "Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by...